Early benefit assessment of medications
Germany evaluates certain new medicines to examine whether they offer added benefit compared with an established treatment. This assessment concerns evidence from groups of patients and is part of the German system for evaluating medicines.
Key takeaway: Germany evaluates certain new medicines to examine whether they offer added benefit compared with an established treatment. This assessment concerns evidence from groups of patients and is part of the German system for evaluating medicines.
On this page
Understanding this topic
An assessment may consider outcomes important to patients, such as symptoms, survival, quality of life and adverse effects. The result depends on the comparison and the evidence available. It is not a personal prescribing recommendation, and German assessment or payment arrangements do not automatically apply in other countries.
Questions to discuss with your healthcare team
- Which patient group and comparison does this assessment concern?
- How relevant are the findings to my treatment choices?
Articles in this topic area
3 articles
Questions about your health?
Talk to a volunteer doctor in a voice call. It is free and confidential.
Don't need a doctor?
A pharmacist can advise you for free, without an appointment.
This guide does not replace a doctor. This page gives you health information. It does not give you a diagnosis or treatment. For that, see a doctor. In an emergency, call 112.